Welcome to our dedicated page for KYNTRA BIO news (Ticker: KYNB), a resource for investors and traders seeking the latest updates and insights on KYNTRA BIO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KYNTRA BIO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KYNTRA BIO's position in the market.
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. CEO Thane Wettig will deliver the company presentation on April 13, 2026 at 1:30 PM EDT. A live webcast and a 90-day replay will be available on the company website.
Management will be available for one-on-one meetings via Needham representative requests.
Kyntra Bio (NASDAQ: KYNB) reported Q4 and full‑year 2025 results and clinical updates on March 16, 2026. Key clinical highlights include an actively enrolling Phase 2 FG‑3246 monotherapy trial in mCRPC with interim analysis expected in 2H 2026, investigator‑sponsored combo data showing median rPFS of 7.0 months (10.1 months in a subgroup), and submission of a pivotal Phase 3 protocol for roxadustat in LR‑MDS. Financials: Q4 2025 revenue $1.3M, FY2025 revenue $6.4M, FY2025 net loss $58.2M, and $109.4M in cash, cash equivalents, investments, and accounts receivable providing runway into 2028.
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close. Management will host a conference call and webcast the same day at 5:00 PM ET to discuss results and provide a business update.
A live Q&A follows the presentation. A replay of the webcast will be available for a limited time on Kyntra Bio’s Events & Presentations page. Phone access requires registration to receive dial-in details.
Kyntra Bio (NASDAQ: KYNB) reported positive investigator‑sponsored Phase 1b/2 data for FG-3246 plus enzalutamide in mCRPC. In 44 biomarker‑unselected patients the combination produced a composite response rate 21% overall and 40% in patients with only one prior ARPI; median rPFS was 7.0 months overall and 10.1 months for one‑prior ARPI patients. The MTD/recommended dose was 2.1 mg/kg FG-3246 with 160 mg/day enzalutamide. Higher FG-3180 PET uptake trended with PSA50 response (p=0.053). Phase 2 monotherapy interim analysis expected in 2H 2026.
Kyntra Bio (Nasdaq: KYNB) announced management will participate in investor conferences in February–March 2026. Presentations: Oppenheimer 36th Annual Healthcare Life Sciences (virtual, Feb 26, 2026, 2:40–3:10 PM ET) and Leerink Global Healthcare Conference (Miami, Mar 11, 2026, 2:20–2:50 PM ET).
Management will be available for one-on-one meetings; webcasts are provided and presentation replays will be posted on the company's Events & Presentations investor page for 90 days.